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Bacteremia Caused 
by Mycobacterium 
wolinskyi
To the Editor:  Mycobacterium 
wolinskyi is a rapidly growing my-
cobacterium that belongs to the M. 
smegmatis group, which includes M. 
smegmatis sensu stricto and 2 species 
described in 1999 (M. goodii and M. 
wolinskyi) (1). Only 9 cases of infec-
tion caused by M. wolinskyi have been 
reported (1–3), and these included 3 
cases of bone infection and 1 case of 
infection of a hip prosthesis. All pa-
tients had a history of surgery after 
traumatic injury and all specimens 
were isolated from the surgical wound. 
In our study, we used molecular diag-
nostic tools and report a case of bacte-
remia caused by M. wolinskyi. 
In November 2006, we diag-
nosed non-Hodgkin lymphoma in a 
22-year-old woman. A venous port 
was implanted, and 4 courses of 
rituximab (anti-CD20 monoclonal 
antibody) plus additional chemother-
apy (cyclophosphamide, epirubicin, 
vicristine and prednisolone) were 
administered from December 2006 
through May 2007. No unfavorable 
sequelae occurred after chemotherapy, 
and the tumor showed a complete re-
sponse. In August 2007, we admitted 
the patient to our hospital because of a 
spiking high fever (up to 40°C), chills, 
and pain in the left knee. On physical 
examination, the patient had a tender, 
warm, erythematous, and swollen left 
knee. These symptoms progressed to 
other joints, including the left hip and 
ankle. 
Laboratory data showed a normal 
leukocyte count (3.4 × 109 cells/L). 
The patient’s C-reactive protein level 
increased from 1.13 mg/dL (on the 
day of admission) to 24.95 mg/dL (7 
days after admission). We drew 2 sets 
of blood samples from a peripheral 
vein for culture and incubated these 
cultures (BACTEC 9240 Continuous 
Monitoring Blood Culture System; 
Becton Dickinson, Sparks, MD, USA) 
using BACTEC Aerobic Plus and An-
aerobic Plus medium (Becton Dickin-
son). Within 3 days, the cultures tested 
positive for acid-fast bacilli.
The isolate was identiﬁ  ed by 16S 
rRNA gene ampliﬁ  cation of an 880-bp 
region (corresponding to positions 27–
907), as previously described (4,5). For 
ampliﬁ   cation, we used broad-range 
primers 16S-27f (5′-AGA GTT TGA 
TCM TGG CTC AG-3′) and 16S-907r 
(5′-CCG TCA ATT CMT TTR AGT 
TT-3′). For sequencing 16S rDNA, we 
used either the primer 16S-27f or 16S-
519r (5′-GWA TTA CCG CGG CKG 
CTG-3′). We performed both forward 
and reverse (5′ and 3′) sequencing. For 
accurate analysis of the data, a 492-bp 
variable region (corresponding to posi-
tions 27– 519) was carefully analyzed 
after it was compared with sequences 
of Mycobacterium spp. in the BLAST 
database (www.ncbi.nlm.nih.gov), as 
described (6). The results showed 99% 
similarity between our isolate and 
M. wolinskyi.
A few days later, we obtained 
synovial  ﬂ  uid by needle biopsy and 
cultured samples in BACTEC Aero-
bic Plus and Anaerobic Plus medium 
(Becton Dickinson) and on trypticase 
soy agar. Within 3 days, these cultures 
were also positive for M. wolinskyi. 
Arthroscopically assisted arthrocente-
sis and debridement showed a turbid 
joint and the debrided tissue showed 
inﬂ   ammatory processes within the 
synovial tissue and the presence of ac-
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Figure. Histologic image of debrided tissue of the patient, showing inﬂ  ammatory processes 
within the synovial tissue and the presence of an acid-fast bacillus (magniﬁ  cation ×400, 
acid-fast stain).LETTERS
id-fast bacilli (Figure). We grew cul-
tures of acid-fast bacilli on trypticase 
soy agar after 2 to 4 days. The colo-
nies were nonchromogenic, smooth 
to mucoid, and off-white to cream 
on Middlebrook 7H10 and trypticase 
soy agar. 
We tested the in vitro antimicro-
bial susceptibility using the broth dilu-
tion method (7). The isolate suscepti-
ble to amikacin, cefoxitin, imipenem, 
doxycycline, and ciproﬂ  oxacin and re-
sistant to sulfamethoxazole, clarithro-
mycin, and tobramycin. We initiated 
treatment of the patient with moxi-
ﬂ   oxacin, minocycline, and amikacin 
1 day after the athroscopy and the pa-
tient’s fever subsided within 72 hours. 
We continued amikacin therapy for 1 
month and administered moxiﬂ  oxacin 
and minocycline for 6 months.
This patient is unique because she 
had a case of bacteremia caused by M. 
wolinskyi, and she had no history of 
major traumatic injury. The bacterium 
might have been introduced during im-
plantation of the venous port or during 
minor trauma that went unnoticed. The 
chemotherapeutic regimen adminis-
tered to our patient may have played a 
role in the infection. Immunosuppres-
sion by treatment with rituximab (an 
anti-CD20 monoclonal antibody) and 
a steroid during chemotherapy may 
have worsened the patient’s B-cell 
function and thereby weakened her 
immunity. Surgical debridement fol-
lowed by antimicrobial therapy for at 
least 6 months is the suggested treat-
ment for M. wolinskyi infection, and 
we followed this regimen. Because 
of the frequency of relapse and resis-
tance, we used combination therapy 
with multiple antimicrobial agents. 
This case suggests that immuno-
compromised patients may be vulner-
able to infection by rapidly growing 
mycobacterium such as M. wolinskyi. 
In such cases, we suggest antimicrobial 
drug treatment, based on in vitro sus-
ceptibility. More data on antimicrobial 
drug susceptibility should be collected 
for treatment of this type of infection.
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Incubation Period 
for Human Cases of 
Avian Inﬂ  uenza A 
(H5N1) Infection, 
China 
To the Editor: Since 1997, more 
than 400 human cases of highly patho-
genic inﬂ  uenza A virus (H5N1) infec-
tion have been reported worldwide, 
including 30 from mainland China. 
Ascertainment of the incubation pe-
riod for inﬂ   uenza virus (H5N1) is 
important to deﬁ  ne exposure periods 
for surveillance of patients with sus-
pected inﬂ  uenza virus (H5N1) infec-
tion. Limited data on the incubation 
period suggest that illness onset oc-
curs <7 days after the last exposure to 
sick or dead poultry (1–4). For clus-
ters in which limited human-to-human 
virus transmission likely occurred, 
the incubation period appeared to be 
3–5 days (5–7) but was estimated to 
be 8–9 days in 1 cluster (5). In China, 
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